Efficacy and Safety of Cilostazol for the Indication of CSPS

NCT00216749 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 650

Last updated 2009-12-17

No results posted yet for this study

Summary

This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.

Conditions

  • Cerebral Infarction

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Bo Youn Seo · Korea Otsuka Pharmaceutical Co., Ltd.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216749 on ClinicalTrials.gov